Pub Date : 2021-03-14DOI: 10.18502/BCCR.V11I3.5720
Masoud Asefi, Nayebali Rezvani, Mohammad Hasan Soheilifar, M. Saidijam, Ali Mahdavinezhad
Colorectal cancer (CRC) is one of the most common cancers worldwide. The beginning and progression of the disease are thought to be determined by combinations of epigenetic and genetic changes that trigger multistep programs of carcinogenesis. In colorectal cancer, epigenetic alterations, in particular promoter CpG island methylation, occur more commonly than genetic mutations. Hyper-methylation contributes to carcinogenesis via inducing transcriptional silencing or down-regulation of tumor suppressor genes. DNA methylation alteration has a high potential for minimally invasive biomarker identification. Genome analysis has confirmed that microRNA expression is deregulated in most cancer types through several mechanisms, including failings in the microRNA biogenesis machinery. Moreover, microRNAs can be dysregulated by abnormal CpG methylation in cancer. Since it is believed that epigenetic changes occur in the early stages of the disease, these changes can be used for the early detection of cancer. In this review, we intend to study the role of microRNA gene promoter methylation in colorectal cancer.
{"title":"MicroRNA Promoter Methylation in Colorectal Cancer","authors":"Masoud Asefi, Nayebali Rezvani, Mohammad Hasan Soheilifar, M. Saidijam, Ali Mahdavinezhad","doi":"10.18502/BCCR.V11I3.5720","DOIUrl":"https://doi.org/10.18502/BCCR.V11I3.5720","url":null,"abstract":"Colorectal cancer (CRC) is one of the most common cancers worldwide. The beginning and progression of the disease are thought to be determined by combinations of epigenetic and genetic changes that trigger multistep programs of carcinogenesis. In colorectal cancer, epigenetic alterations, in particular promoter CpG island methylation, occur more commonly than genetic mutations. Hyper-methylation contributes to carcinogenesis via inducing transcriptional silencing or down-regulation of tumor suppressor genes. DNA methylation alteration has a high potential for minimally invasive biomarker identification. Genome analysis has confirmed that microRNA expression is deregulated in most cancer types through several mechanisms, including failings in the microRNA biogenesis machinery. Moreover, microRNAs can be dysregulated by abnormal CpG methylation in cancer. Since it is believed that epigenetic changes occur in the early stages of the disease, these changes can be used for the early detection of cancer. In this review, we intend to study the role of microRNA gene promoter methylation in colorectal cancer.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"2 1","pages":"135-141"},"PeriodicalIF":0.0,"publicationDate":"2021-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90733906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-14DOI: 10.18502/BCCR.V11I4.5722
M. Rezaei, M. Toutkaboni, Babak Salimi, S. Seifi, F. Sheikholeslami
Background: A substitution of G to T at nucleotide 1849 in exon 14 of the Janus kinase2 (JAK2) gene is well recognized in myeloproliferative neoplastic disorders (MPNs). Based on WHO guidelines, detection of the mutation is very important to confirm the disease in suspected patients. Methods: Eighty-seven patients with different background diseases were tested for JAK2 V617F mutation by four different methods, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), amplification refractory mutation system (ARMS), polymerase chain reaction-high resolution melting (PCR-HRM), and two different commercial kits. Results: The mean age of patients was 53.38±17.43 years, 72.4% were males, and 37.6% were females. JAK2 mutation was detected in 16 patients (18.3%). Of those, 7 (43.75%) suffered from PV, 5 (31.25%) from ET, 3 (18.75%) from PMF, and 1 (6.15%) from unclassified neoplastic disorders. The frequency of JAK2 mutation was 71.4% (5/7) in PV, 80% (4/5) in ET, and 66.7% (2/3) in PMF patients. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and GE of PCR-HRM for detection of the JAK2 mutation was 86.7%, 100%, 100%, 97.3%, and 97.7%, respectively. While the sensitivity, specificity, PPV, NPV, and GE of PCR-RFLP were 93.3%, 80.5%, 50%, 98.3%, and 82.7%, respectively. On the other hand, the sensitivity, specificity, PPV, NPV, and GE of ARMS assays were evaluated by about 80%, 96%, 100%, 96%, and 96.5%, respectively. Conclusion: This study showed that PCR-HRM was a more sensitive assay to detect the JAK2 V617F mutation than the other assays. So, it can be used as a quick, easy, and effective method for screening the JAK2 V617F mutation in patients with MPNs disorders. PCR-RFLP must accompany it as a gold standard method for confirmation of the mutation of JAK2 V617F.
{"title":"PCR-HRM for Detecting JAK2V617F Gene Mutation: Is It a Sensitive Assay?","authors":"M. Rezaei, M. Toutkaboni, Babak Salimi, S. Seifi, F. Sheikholeslami","doi":"10.18502/BCCR.V11I4.5722","DOIUrl":"https://doi.org/10.18502/BCCR.V11I4.5722","url":null,"abstract":"Background: A substitution of G to T at nucleotide 1849 in exon 14 of the Janus kinase2 (JAK2) gene is well recognized in myeloproliferative neoplastic disorders (MPNs). Based on WHO guidelines, detection of the mutation is very important to confirm the disease in suspected patients. Methods: Eighty-seven patients with different background diseases were tested for JAK2 V617F mutation by four different methods, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), amplification refractory mutation system (ARMS), polymerase chain reaction-high resolution melting (PCR-HRM), and two different commercial kits. Results: The mean age of patients was 53.38±17.43 years, 72.4% were males, and 37.6% were females. JAK2 mutation was detected in 16 patients (18.3%). Of those, 7 (43.75%) suffered from PV, 5 (31.25%) from ET, 3 (18.75%) from PMF, and 1 (6.15%) from unclassified neoplastic disorders. The frequency of JAK2 mutation was 71.4% (5/7) in PV, 80% (4/5) in ET, and 66.7% (2/3) in PMF patients. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and GE of PCR-HRM for detection of the JAK2 mutation was 86.7%, 100%, 100%, 97.3%, and 97.7%, respectively. While the sensitivity, specificity, PPV, NPV, and GE of PCR-RFLP were 93.3%, 80.5%, 50%, 98.3%, and 82.7%, respectively. On the other hand, the sensitivity, specificity, PPV, NPV, and GE of ARMS assays were evaluated by about 80%, 96%, 100%, 96%, and 96.5%, respectively. Conclusion: This study showed that PCR-HRM was a more sensitive assay to detect the JAK2 V617F mutation than the other assays. So, it can be used as a quick, easy, and effective method for screening the JAK2 V617F mutation in patients with MPNs disorders. PCR-RFLP must accompany it as a gold standard method for confirmation of the mutation of JAK2 V617F.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"95 1","pages":"173-181"},"PeriodicalIF":0.0,"publicationDate":"2021-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78204419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-23DOI: 10.18502/bccr.v11i2.1659
A. Shaghaghi, Roya Yousefian
Benign multicystic peritoneal mesothelioma (BMPM) is a rare disorder that occurs predominantly in reproductive-aged women. A 42-year-old male referred to our emergency department in Mousavi Hospital of Zanjan University, suffering from diffuse abdominal pain. He mentioned a history of operation two years ago, during which cystic tumors had been removed from his abdomen. A cytoreductive surgery was performed. The pathologic study confirmed the diagnosis of BMPM and immunohistochemical analysis verified the negative expression of CD34 marker and positive expression of calretinine in the cyst lining. Preoperative diagnosis of BMPM is difficult and definitive diagnosis requires histological evaluation of the specimen. Due to the rarity of BMPM, the need for familiarity with this benign but aggressive tumor is felt.
{"title":"Benign Multi-Cystic Peritoneal Mesothelioma: A Case Report","authors":"A. Shaghaghi, Roya Yousefian","doi":"10.18502/bccr.v11i2.1659","DOIUrl":"https://doi.org/10.18502/bccr.v11i2.1659","url":null,"abstract":"Benign multicystic peritoneal mesothelioma (BMPM) is a rare disorder that occurs predominantly in reproductive-aged women. A 42-year-old male referred to our emergency department in Mousavi Hospital of Zanjan University, suffering from diffuse abdominal pain. He mentioned a history of operation two years ago, during which cystic tumors had been removed from his abdomen. A cytoreductive surgery was performed. The pathologic study confirmed the diagnosis of BMPM and immunohistochemical analysis verified the negative expression of CD34 marker and positive expression of calretinine in the cyst lining. Preoperative diagnosis of BMPM is difficult and definitive diagnosis requires histological evaluation of the specimen. Due to the rarity of BMPM, the need for familiarity with this benign but aggressive tumor is felt.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74690543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-23DOI: 10.18502/BCCR.V11I2.1657
M. M. Davudov, I. Harirchi, Z. Mirzajani
Background: One of the main goals of patient management is the reconstruction of tissue defects following surgical resection for oral cancer. A variety of flaps used for this purpose, the most frequent being a Pectoralis Major Myocutaneus Flap (PMMF). This flap is currently widely used for the reconstruction of different defects of the head and neck. Methods: Surgical resection of the primary tumor, as well as neck dissection, performed on 29 patients with oral squamous cell carcinoma between 2011–2017 in City Hospital #1 and Surgical Training Clinic of Azerbaijan Medical University. PMMF used for the reconstruction of defects using a deltopectoral flap incision. Results: In 22 patients (75.8 %) primary healing occurred following a PMMF. Four patients (13.8 %) suffered PMMF necrosis and were took back to the operating room for secondary reconstruction with a deltopectoral flap. In three patients (10.3%) the skin of the flap underwent necrosis, resulting in the development of an orocutaneous fistula. Conclusion: Use of PMMF with deltopectoral flap incision enables deltopectoral flap availability. This flap can then used early on or if PMMF fails.
{"title":"Pectoralis Major Myocutaneous Flap Reconstruction with Deltopectoral Flap Incision in the Surgical Treatment of Oral Cancer","authors":"M. M. Davudov, I. Harirchi, Z. Mirzajani","doi":"10.18502/BCCR.V11I2.1657","DOIUrl":"https://doi.org/10.18502/BCCR.V11I2.1657","url":null,"abstract":"Background: One of the main goals of patient management is the reconstruction of tissue defects following surgical resection for oral cancer. A variety of flaps used for this purpose, the most frequent being a Pectoralis Major Myocutaneus Flap (PMMF). This flap is currently widely used for the reconstruction of different defects of the head and neck. Methods: Surgical resection of the primary tumor, as well as neck dissection, performed on 29 patients with oral squamous cell carcinoma between 2011–2017 in City Hospital #1 and Surgical Training Clinic of Azerbaijan Medical University. PMMF used for the reconstruction of defects using a deltopectoral flap incision. Results: In 22 patients (75.8 %) primary healing occurred following a PMMF. Four patients (13.8 %) suffered PMMF necrosis and were took back to the operating room for secondary reconstruction with a deltopectoral flap. In three patients (10.3%) the skin of the flap underwent necrosis, resulting in the development of an orocutaneous fistula. Conclusion: Use of PMMF with deltopectoral flap incision enables deltopectoral flap availability. This flap can then used early on or if PMMF fails.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90292256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-09DOI: 10.18502/BCCR.V11I2.1654
M. Mobasheri
The article's abstract is no available.
这篇文章的摘要找不到。
{"title":"Metabolomics in Cancer","authors":"M. Mobasheri","doi":"10.18502/BCCR.V11I2.1654","DOIUrl":"https://doi.org/10.18502/BCCR.V11I2.1654","url":null,"abstract":"The article's abstract is no available.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74254398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-26DOI: 10.18502/BCCR.V11I2.1658
M. Mobasheri, Rahim Behtar, S. Sadighi
According to the studies the rate of emergency departments use among cancer patients exceed those of general population; however, there are differences based on cancer type, initial treatments, socioeconomic status, disease stages, health insurance status and so on. Patients’ symptoms and the severity of complications are varied as well. The emergency departments are actively involved in different stages of cancer management such as primary diagnosis, ongoing treatments and end-of-life period. Cancer patients usually have more serious complications and need more specialized cares at the end of life period, during chemotherapy and surgical treatments. Understanding the reasons for such visits could be useful in the development of dedicated interventions for preventing unnecessary emergency department visits, which is discussed in this mini-review.
{"title":"Challenges with the Emergency Departments Use among Cancer Patients; a Mini Review","authors":"M. Mobasheri, Rahim Behtar, S. Sadighi","doi":"10.18502/BCCR.V11I2.1658","DOIUrl":"https://doi.org/10.18502/BCCR.V11I2.1658","url":null,"abstract":"According to the studies the rate of emergency departments use among cancer patients exceed those of general population; however, there are differences based on cancer type, initial treatments, socioeconomic status, disease stages, health insurance status and so on. Patients’ symptoms and the severity of complications are varied as well. The emergency departments are actively involved in different stages of cancer management such as primary diagnosis, ongoing treatments and end-of-life period. Cancer patients usually have more serious complications and need more specialized cares at the end of life period, during chemotherapy and surgical treatments. Understanding the reasons for such visits could be useful in the development of dedicated interventions for preventing unnecessary emergency department visits, which is discussed in this mini-review.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89699437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-09DOI: 10.18502/bccr.v11i2.1656
M. Ayati, E. Amini, M. Nowroozi, Seyed Ali Momeni, S. O. Moghadam, R. S. Damavand
Background: To evaluate the efficacy of Bioceram injection in men with severe stress urinary incontinence following radical prostatectomy. Methods: A total of 18 patients underwent retrograde injection of Bioceram for severe stress urinary incontinence following radical prostatectomy. Evaluation by pad test, international consultation on the Incontinence Questionnaire - Short Form (ICIQ-SF) and American Urology Association Symptom Score - Quality of Life (AUASS-QOL) was performed before and after injection therapy. Patients were considered cured if they were using no pads or only one safety pad per day. Results: Of 18 patients, 14 had received postoperative external beam radiation therapy. Furthermore, 5 patients required transurethral incision due to simultaneous stricture of the urethrovesical anastomosis. The baseline daily pad count changed from a mean of 6.1± 0.8 to 5.3 ± 1.7 (p = 0.010). None of the patients were cured and only 3 patients showed signs of improvement following injection. Conclusion: In patients with severe urinary incontinence, treatment with bulking agent injection is associated with modest efficacy.
{"title":"Treatment of Severe Urinary Incontinence following Radical Prostatectomy: Experience with Bioceram as a Bulking Agent","authors":"M. Ayati, E. Amini, M. Nowroozi, Seyed Ali Momeni, S. O. Moghadam, R. S. Damavand","doi":"10.18502/bccr.v11i2.1656","DOIUrl":"https://doi.org/10.18502/bccr.v11i2.1656","url":null,"abstract":"Background: To evaluate the efficacy of Bioceram injection in men with severe stress urinary incontinence following radical prostatectomy. Methods: A total of 18 patients underwent retrograde injection of Bioceram for severe stress urinary incontinence following radical prostatectomy. Evaluation by pad test, international consultation on the Incontinence Questionnaire - Short Form (ICIQ-SF) and American Urology Association Symptom Score - Quality of Life (AUASS-QOL) was performed before and after injection therapy. Patients were considered cured if they were using no pads or only one safety pad per day. Results: Of 18 patients, 14 had received postoperative external beam radiation therapy. Furthermore, 5 patients required transurethral incision due to simultaneous stricture of the urethrovesical anastomosis. The baseline daily pad count changed from a mean of 6.1± 0.8 to 5.3 ± 1.7 (p = 0.010). None of the patients were cured and only 3 patients showed signs of improvement following injection. Conclusion: In patients with severe urinary incontinence, treatment with bulking agent injection is associated with modest efficacy.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85482216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-09DOI: 10.18502/BCCR.V11I2.1655
A. Amirzargar, M. Sadr, Samira Esmaeili Reykande, E. Mohebbi, Mohammad Shirkhoda, M. Mahmoodi
Background: Estrogen is a risk factor for the development of breast cancer. The effect of estrogen is primarily mediated by estrogen receptor alpha 1 (ESR1). In this study, we investigated the association between breast cancer risk and the frequency of alleles and genotypes for two ESR1 single nucleotide polymorphisms (SNPs) in breast cancer patients and a healthy control group. Methods: A total of 98 female patients with pathologically confirmed breast cancer and 93 age-matched healthy female controls who were selected from the visitors of the general hospital were recruited in the study. Two ESR1 candidate polymorphisms; +2464 C/T (rs3020314) and -4576 A/C (rs1514348) were selected. The frequency of alleles and genotypes was determined using Quantitative Real-Time PCR assay. Linkage disequilibrium (LD) was assessed for each pair of markers. Using logistic regression, genotype frequencies were estimated as odds ratios with 95% confidence intervals. Results: There was no significant difference in the genotype and allele distributions of ESR1 for SNPs +2464 C/T and SNP -4576 A/C between patients and controls. The frequency of the ESR1 +2464 T/T genotype in case and control groups was 31.6% vs 29.0%, (OR TT/TC: 1.13, 95%CI: 0.58, 2.20; P = 0.69). The frequency of the +2464C allele was 33.9% vs 35.2%, (OR C/T: 0.94, 95%CI: 0.60, 1.47; P =0.79). The frequency of the ESR1 -4576C/C genotype in case and control groups was 37.75% vs 33.36%, OR CC/AC: 1.02, 95%CI: 0.51, 1.97; P =0.98). The frequency of the -4576A allele was 36.2% vs 43.6 %, (OR C/A: 0.73, 95%CI: 0.47, 1.13; P =0.14). Conclusion: The results indicated that ESR1 polymorphism does not show any significant association with breast cancer risk among female Iranian adults.
{"title":"Estrogen Receptor Alpha Gene Single Nucleotide Polymorphisms, +2464 C/T and -4576A/C, and Breast Cancer Risk, a Hospital-Based Case-Control Study","authors":"A. Amirzargar, M. Sadr, Samira Esmaeili Reykande, E. Mohebbi, Mohammad Shirkhoda, M. Mahmoodi","doi":"10.18502/BCCR.V11I2.1655","DOIUrl":"https://doi.org/10.18502/BCCR.V11I2.1655","url":null,"abstract":"Background: Estrogen is a risk factor for the development of breast cancer. The effect of estrogen is primarily mediated by estrogen receptor alpha 1 (ESR1). In this study, we investigated the association between breast cancer risk and the frequency of alleles and genotypes for two ESR1 single nucleotide polymorphisms (SNPs) in breast cancer patients and a healthy control group. Methods: A total of 98 female patients with pathologically confirmed breast cancer and 93 age-matched healthy female controls who were selected from the visitors of the general hospital were recruited in the study. Two ESR1 candidate polymorphisms; +2464 C/T (rs3020314) and -4576 A/C (rs1514348) were selected. The frequency of alleles and genotypes was determined using Quantitative Real-Time PCR assay. Linkage disequilibrium (LD) was assessed for each pair of markers. Using logistic regression, genotype frequencies were estimated as odds ratios with 95% confidence intervals. Results: There was no significant difference in the genotype and allele distributions of ESR1 for SNPs +2464 C/T and SNP -4576 A/C between patients and controls. The frequency of the ESR1 +2464 T/T genotype in case and control groups was 31.6% vs 29.0%, (OR TT/TC: 1.13, 95%CI: 0.58, 2.20; P = 0.69). The frequency of the +2464C allele was 33.9% vs 35.2%, (OR C/T: 0.94, 95%CI: 0.60, 1.47; P =0.79). The frequency of the ESR1 -4576C/C genotype in case and control groups was 37.75% vs 33.36%, OR CC/AC: 1.02, 95%CI: 0.51, 1.97; P =0.98). The frequency of the -4576A allele was 36.2% vs 43.6 %, (OR C/A: 0.73, 95%CI: 0.47, 1.13; P =0.14). Conclusion: The results indicated that ESR1 polymorphism does not show any significant association with breast cancer risk among female Iranian adults.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81345023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-16DOI: 10.18502/BCCR.V11I1.1650
S. Mohammadpur, M. Yousefi, H. Ebrahimipur, Touraj Harati-Khalilabad, H. Haghighi, M. Kiani, S. Shahidsales, A. Taghipour
Background: Approximately 20 million individuals are afflicted with cancer worldwide. Gastric cancer is the fourth leading cause of death in the world today. The aim of this study was to evaluate the direct medical care costs of gastric cancer patients in a tertiary teaching hospital in Iran. Methods: The present study is descriptive-analytical, carried out in two main stages. In the first stage we designed a form based on valid international guidelines. The second step identified the costs of diagnosis and treatment of gastric cancer. To analyze the cost data, descriptive statistics such as mean and standard deviation were utilized. We used nonparametric statistical tests such as Mann-Whitney, Wilcoxon in SPSS 16 software for data analysis. Results: In this study, the records of 449 gastric cancer patients who had referred to Omid tertiary teaching hospital of Mashhad between the years 2005 and 2015 were studied. According to the results, the highest average costs were related to patient hospitalization costs. Based on the significance level of the Mann Whitney test, no remarkable difference could be seen in the total costs of metastatic and non-metastatic patients (P-value: P> 0.05). Conclusion: Organizations such as: insurance agencies, charities and financial institutions need to adopt new policies to reduce patients’ expenditures, remove financial barriers and prevent patients from facing catastrophic costs.
{"title":"The Direct Medical Care Costs Associated with Gastric Cancer in a Third-level Hospital in Iran","authors":"S. Mohammadpur, M. Yousefi, H. Ebrahimipur, Touraj Harati-Khalilabad, H. Haghighi, M. Kiani, S. Shahidsales, A. Taghipour","doi":"10.18502/BCCR.V11I1.1650","DOIUrl":"https://doi.org/10.18502/BCCR.V11I1.1650","url":null,"abstract":"Background: Approximately 20 million individuals are afflicted with cancer worldwide. Gastric cancer is the fourth leading cause of death in the world today. The aim of this study was to evaluate the direct medical care costs of gastric cancer patients in a tertiary teaching hospital in Iran. Methods: The present study is descriptive-analytical, carried out in two main stages. In the first stage we designed a form based on valid international guidelines. The second step identified the costs of diagnosis and treatment of gastric cancer. To analyze the cost data, descriptive statistics such as mean and standard deviation were utilized. We used nonparametric statistical tests such as Mann-Whitney, Wilcoxon in SPSS 16 software for data analysis. Results: In this study, the records of 449 gastric cancer patients who had referred to Omid tertiary teaching hospital of Mashhad between the years 2005 and 2015 were studied. According to the results, the highest average costs were related to patient hospitalization costs. Based on the significance level of the Mann Whitney test, no remarkable difference could be seen in the total costs of metastatic and non-metastatic patients (P-value: P> 0.05). Conclusion: Organizations such as: insurance agencies, charities and financial institutions need to adopt new policies to reduce patients’ expenditures, remove financial barriers and prevent patients from facing catastrophic costs.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79725548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-14DOI: 10.18502/BCCR.V11I1.1651
Sara Mirhadi, A. Abbasi, M. Mobasheri, H. Moslehi, M. Modarressi
Background: Basal Cell Carcinoma (BCC) with its slow-growing and rarely metastatic nature is the most common human neoplasm. Multiple BCCs mostly result from germline mutations in the tumor suppressor gene, PTCH with a genetic transmission pattern. Multiple BCCs may also originate from radiodermatitis which is a significant side effect of ionizing radiation exposure delivered to the skin in various skin treatments. PTCH is a critical member of the Sonic Hedgehog signalling pathway and mutations in this gene have been reported in as many as 40-80% of skin cancers. Exon number 23 is a critical exon in the function of the PTCH protein. Mutations have been reported in codon 1315 of PTCH in non-melanoma skin cancers. Methods: We assessed mutations in exon 23 of the PTCH gene by polymerase chain reaction and direct sequencing in the peripheral blood cells of 10 patients with multiple BCCs. All of the subjects were selected from among patients with a history of radiation exposure and subsequent radiodermatitis. Results: Direct sequencing revealed a Cytosine to Thymine mutation in codon 1315 of the PTCH gene in 60% of patients, 50% of which were heterozygotes, possessing both the C and T allele, and 10% were homozygotes for the T allele in the same position. Four subjects (40%) were normal homozygotes of the C allele, similar to the normal population. Conclusion: Mutations with ID: rs 3575564 were detected in codon 1315 which transform the proline amino-acid to leucine in the PTCH protein. This transformation may affect the normal function of the PTCH protein, as reported previously. Patients with multiple BCCs who had a history of radiation exposure show a transformation from cytosine to thymine in codon number 1315 of the PTCH gene in their peripheral blood cells. Subsequent assessment of BCC tissues will clarify the somatic mutagenesis effects of radiation.
{"title":"Mutation Analysis of Exon 23 of the PTCH Tumor Suppressor Gene in Multiple Basal Cell Carcinoma Patients with a History of Radiodermatitis","authors":"Sara Mirhadi, A. Abbasi, M. Mobasheri, H. Moslehi, M. Modarressi","doi":"10.18502/BCCR.V11I1.1651","DOIUrl":"https://doi.org/10.18502/BCCR.V11I1.1651","url":null,"abstract":"Background: Basal Cell Carcinoma (BCC) with its slow-growing and rarely metastatic nature is the most common human neoplasm. Multiple BCCs mostly result from germline mutations in the tumor suppressor gene, PTCH with a genetic transmission pattern. Multiple BCCs may also originate from radiodermatitis which is a significant side effect of ionizing radiation exposure delivered to the skin in various skin treatments. PTCH is a critical member of the Sonic Hedgehog signalling pathway and mutations in this gene have been reported in as many as 40-80% of skin cancers. Exon number 23 is a critical exon in the function of the PTCH protein. Mutations have been reported in codon 1315 of PTCH in non-melanoma skin cancers. Methods: We assessed mutations in exon 23 of the PTCH gene by polymerase chain reaction and direct sequencing in the peripheral blood cells of 10 patients with multiple BCCs. All of the subjects were selected from among patients with a history of radiation exposure and subsequent radiodermatitis. Results: Direct sequencing revealed a Cytosine to Thymine mutation in codon 1315 of the PTCH gene in 60% of patients, 50% of which were heterozygotes, possessing both the C and T allele, and 10% were homozygotes for the T allele in the same position. Four subjects (40%) were normal homozygotes of the C allele, similar to the normal population. Conclusion: Mutations with ID: rs 3575564 were detected in codon 1315 which transform the proline amino-acid to leucine in the PTCH protein. This transformation may affect the normal function of the PTCH protein, as reported previously. Patients with multiple BCCs who had a history of radiation exposure show a transformation from cytosine to thymine in codon number 1315 of the PTCH gene in their peripheral blood cells. Subsequent assessment of BCC tissues will clarify the somatic mutagenesis effects of radiation.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89028890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：